Chemists Make Discovery That May Lead To Drug Treatment Possibilities For Alzheimer's
February 14, 2011
Adapted from University of California (UC) - Santa Barbara
UC Santa Barbara scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes. Their work is published in a recent issue of Nature Chemistry.
The amyloid diseases are characterized by plaque that aggregates into toxic agents that interact with cellular machinery, explained Michael T. Bowers, lead author and professor in the Department of Chemistry and Biochemistry. Other amyloid diseases include Parkinson's disease, Huntington's disease, and atherosclerosis. Amyloid plaques are protein fibrils that, in the case of Alzheimer's disease, develop prior to the appearance of symptoms.
"The systems we use are model systems, but the results are groundbreaking," said Bowers. He explained that his research provides the first examples of the conversion of randomly assembled aggregates of small peptides into ordered beta sheets that comprise fibrils. Fibrils are the final structural state of the aggregation process.
In the article, Bowers describes how understanding the fundamental forces that relate aggregation, shape, and biochemistry of soluble peptide aggregates is central to developing diagnostic and therapeutic strategies for amyloid diseases.
Bowers and his research team used a method called ion-mobility spectrometry-mass spectrometry (IMS-MS). This method enabled the team to deduce the peptide self-assembly method. They then examined a series of amyloid-forming peptides clipped from larger peptides or proteins associated with disease.
Bowers explained that IMS-MS has the potential to open new avenues for investigating the pathogenic mechanisms of amyloid diseases, their early diagnosis and eventual treatment.
View all news updates for Alzheimer's disease
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.